Suraksha Diagnostic earnings calls.

Suraksha Diagnostic delivered 30% YoY revenue growthCurrent reported value: 30% YoY revenue growth. No comparable prior figure is available in the source record. in Q3 FY26 driven by volume expansion and genomics vertical traction. Total income reached ₹78.3 croreCurrent reported value: ₹78.3 crore. No comparable prior figure is available in the source record. with EBITDA at ₹24 croreCurrent reported value: ₹24 crore. No comparable prior figure is available in the source record. (30.6% margin), though margins compressed 200bps YoY due to pre-operative costs from 24 new centers, of which 18 are less than a year old. PAT grew 21Current reported value: 21. No comparable prior figure is available in the source record.% to ₹7.2 croreCurrent reported value: ₹7.2 crore. No comparable prior figure is available in the source record.. The company commissioned 12 new centersCurrent 12 new centers. Reported change: +New in 9M. in 9 months with 6 more in execution. Genomics vertical (Suraksha Sutra) achieved ₹53 lakhCurrent ₹53 lakh. Reported change: +New Vertical. monthly revenue run rate with management targeting ₹4+ croreCurrent reported value: ₹4+ crore. No comparable prior figure is available in the source record. annual run rate in FY27. Revenue per patient declined to ₹2,140 due to new market penetration. The company reiterates margin recovery to 33-34% by FY27 Q3 as new centers mature, prioritizing scale over near-term profitability. Management targets 100 centers by FY28Current reported value: 100 centers by FY28. No comparable prior figure is available in the source record. with 12-15 centers annually. Key risks include competitive genomic launches by Dr. Lal and Metropolis, margin pressure from expansion, and PPP receivables. Market positioning remains focused on eastern India where Suraksha is the only player with complete genomic capabilities.